


In collaboration with



Facing the Challenges: Equity, Sustainability and Access

29-30 November 2018

INFARMED | Lisbon - PORTUGAL





CHANTAL BÉLORGEY

PROFILE

Chantal Bélorgey, MD, PhD, is the Head of the Health Technology Assessment and Public Health division at the French Health Authority (Haute Autorité de Santé - HAS).

The division is in charge of providing scientific expertise (clinical and medico-economics) for health technologies reimbursement and price decisions. It covers pharmaceuticals, medical devices and other technologies including public health recommendations.

Within EunetHTA, the European network of HTA bodies, her team at HAS is leading the WP5 in charge of early dialogues and post launch evidence generation and she is the Vice Chair of EUnetHTA executive board.

Before joining HAS in June 2016, Chantal Bélorgey led the Department of Medicines, clinical practice Recommendations, and Quality of expertise at the French National Cancer Institute (INCa).

Previously, she was the counselor of the French Minister of Health (2012-2014), in charge of Health products and technologies, and served for many years at the French regulatory National Agency of Health Products (ANSM) where she particularly headed the Division of Medicines in oncohematology and the Department of clinical trials and expanded access/compassionate use programs.